ABCL AbCellera Biologics Inc.
ABCL AbCellera Biologics Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $3.52 · VWAP $6.53 · +81.1% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster
Coverage
1 related campaign
ABCL Price Structure
Loading timeframes…
Peers
Every watchlist ABCL belongs to, members best 30-day change first — ABCL highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-capital-cycle
@ibb
Reported the quarter ending 2026-06-30: revenue $4M, diluted EPS -$0.18, net income -$55M (SEC filing, revenue corroborated by the desk's provider cache). Across the print the stock moved +7.2% (close before → first close after).
full note →Against street estimates
How ABCL's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
News (last pull)
Headlines about ABCL from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 16 days ago · Oct 7
- AbCellera Biologics (Nasdaq:ABCL) - Aktienanalyse - Simply Wall St
- abcellera biologics inc
- AbCellera Biologics Inc. - AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
- Latest news about AbCellera Biologics Inc. - MarketScreener
- AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
ABCL research tape
116 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to ABCL.
Vertical: Biotech Capital Cycle — the theme is confirmed; the question is now entries
ABCL — watch above $8.45
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet